UK study to test Pfizer COVID drug Paxlovid in hospitalised patients
Recovery, led by the University of Oxford, will probe whether Paxlovid shortens the length of hospital stay or reduces the need for a mechanical ventilator, they added.
New Delhi: Pfizer's oral COVID-19 therapy will be evaluated as a potential treatment for patients hospitalised with the illness in a major British trial, scientists said on Monday, as cases rise in some parts of the world.
The world's largest randomised study of potential medicines for COVID-19, dubbed the RECOVERY trial, will assess Paxlovid across hospitals in Britain, which has already approved the drug for early-stage treatment.
"Paxlovid is a promising oral antiviral drug but we don't know if it can improve survival of patients with severe COVID-19," said Peter Horby, a professor at the University of Oxford and joint chief investigator of the RECOVERY trial.
The scientists said they aim to mainly find whether Pfizer's Paxlovid reduces the risk of death among patients admitted to hospitals with COVID-19.
Earlier this year, the trial began testing a rival COVID-19 pill from Merck for hospitalised patients as well.
Read also: Etrasimod Phase 3 trial shows positive results in Ulcerative Colitis patients: Pfizer
RECOVERY, led by the University of Oxford, will also probe whether Paxlovid shortens the length of hospital stay or reduces the need for a mechanical ventilator, they added.
Paxlovid is part of a class of drugs called protease inhibitors, currently used to treat HIV, hepatitis C as well as other viruses, and works by stopping the virus from replicating.
Pfizer, which is now testing Paxlovid for use in children, has said it expects more than $20 billion in sales from Paxlovid this year.
Scientists behind the RECOVERY trial in 2020 showed that dexamethasone, a steroid, was able to save the lives of patients in a "major breakthrough" in the pandemic. They also discovered the effectiveness of treatments such as arthritis drug tocilizumab and antibody cocktail Ronapreve.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.